BR112024000731A2 - População de células exterminadoras naturais de memória purificadas, células nk de memória, método para produzir células nk de memória, e, método para tratar uma malignidade proliferativa - Google Patents

População de células exterminadoras naturais de memória purificadas, células nk de memória, método para produzir células nk de memória, e, método para tratar uma malignidade proliferativa

Info

Publication number
BR112024000731A2
BR112024000731A2 BR112024000731A BR112024000731A BR112024000731A2 BR 112024000731 A2 BR112024000731 A2 BR 112024000731A2 BR 112024000731 A BR112024000731 A BR 112024000731A BR 112024000731 A BR112024000731 A BR 112024000731A BR 112024000731 A2 BR112024000731 A2 BR 112024000731A2
Authority
BR
Brazil
Prior art keywords
cells
memory
producing
population
treating
Prior art date
Application number
BR112024000731A
Other languages
English (en)
Inventor
L Govero Jennifer
M Chrobak Kenneth
Elizabeth Mathyer Mary
Matthew Cooper
Patrick Sullivan Ryan
Original Assignee
Wugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wugen Inc filed Critical Wugen Inc
Publication of BR112024000731A2 publication Critical patent/BR112024000731A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

população de células exterminadoras naturais de memória purificadas, células nk de memória, método para produzir células nk de memória, e, método para tratar uma malignidade proliferativa. a presente revelação se refere, de modo geral, entre outros, a células exterminadoras naturais (nk) que incluem células nk do tipo memória e do tipo memória induzidas por citocina (ciml), a métodos para produzi-las e usá-las, por exemplo, no tratamento de câncer, no aumento de propriedades antitumorais de células nk.
BR112024000731A 2021-07-15 2022-07-14 População de células exterminadoras naturais de memória purificadas, células nk de memória, método para produzir células nk de memória, e, método para tratar uma malignidade proliferativa BR112024000731A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222306P 2021-07-15 2021-07-15
PCT/US2022/037178 WO2023288007A2 (en) 2021-07-15 2022-07-14 Expansion of memory natural killer cells

Publications (1)

Publication Number Publication Date
BR112024000731A2 true BR112024000731A2 (pt) 2024-04-30

Family

ID=84920491

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112024000731A BR112024000731A2 (pt) 2021-07-15 2022-07-14 População de células exterminadoras naturais de memória purificadas, células nk de memória, método para produzir células nk de memória, e, método para tratar uma malignidade proliferativa

Country Status (8)

Country Link
EP (1) EP4370138A2 (pt)
JP (1) JP2024527408A (pt)
KR (1) KR20240035846A (pt)
CN (1) CN117729928A (pt)
AU (1) AU2022312462A1 (pt)
BR (1) BR112024000731A2 (pt)
CA (1) CA3226688A1 (pt)
WO (1) WO2023288007A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116875548B (zh) * 2023-09-08 2024-01-02 山东康华生物医疗科技股份有限公司 一种nk细胞活性培养管及其生产工艺
CN117143815B (zh) * 2023-10-30 2024-01-26 再少年(北京)生物科技有限公司 工程化记忆样nk细胞的制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200392457A1 (en) * 2016-07-25 2020-12-17 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of producing modified natural killer cells and methods of use
EP3987010A1 (en) * 2019-06-21 2022-04-27 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof

Also Published As

Publication number Publication date
WO2023288007A2 (en) 2023-01-19
WO2023288007A3 (en) 2023-04-06
JP2024527408A (ja) 2024-07-24
AU2022312462A1 (en) 2024-01-25
KR20240035846A (ko) 2024-03-18
EP4370138A2 (en) 2024-05-22
CA3226688A1 (en) 2023-01-19
WO2023288007A9 (en) 2023-06-08
CN117729928A (zh) 2024-03-19

Similar Documents

Publication Publication Date Title
BR112024000731A2 (pt) População de células exterminadoras naturais de memória purificadas, células nk de memória, método para produzir células nk de memória, e, método para tratar uma malignidade proliferativa
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
ECSP19043254A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2
BR112019009925A2 (pt) método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
CL2022002808A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CO2017013432A2 (es) Compuestos de indazol-fenil-fenoxi-enamida y sus variaciones
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
CO2020004906A2 (es) Composiciones y métodos para la eliminación de células cd117+
NZ736853A (en) Methods of treating cancer patients with farnesyl transferase inhibitors
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
MX2023008193A (es) Procedimientos para tratar el cáncer.
MX2022005345A (es) Terapia de combinación para el tratamiento de cáncer cerebral.
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
WO2019054632A3 (ko) 집중력 향상을 위한 안경 장치
CA3156667A1 (en) OLIGONUCLEOTIDES INCLUDING NUCLEOSIDE ANALOGS
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
BR112022001045A2 (pt) Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
MX2024006078A (es) Metodo para tratar el cancer con acilfulveno y radiacion.
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
AR052346A1 (es) Composicion que comprende una epotilona y metodos para producir dicha composicion
CO2022009433A2 (es) Uso de isatuximab para el tratamiento del mieloma múltiple recidivante y/o refractario